TAS-0612 is under clinical development by Taiho Oncology and currently in Phase I for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer). According to GlobalData, Phase I drugs for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) have a 90% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TAS-0612’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

TAS-0612 overview

TAS-0612 is under development for the treatment of solid tumors including HER2 negative breast cancer and triple negative breast cancer. It is administered by oral route as tablets. It targets protein kinase B (AKT), 70 kDa ribosomal protein S6 kinase (p70S6K) and ribosomal protein S6 kinase alpha 3 (pp90RSK2).

Taiho Oncology overview

Taiho Oncology, a subsidiary of Taiho Pharmaceutical Co Ltd, is a provider of cancer treatments and solutions. The company manufactures and markets cancer anti-metabolites as well as targeted small molecule inhibitors. Its products portfolio includes oral drugs for the treatment of gastric cancer, colorectal cancer and a variety of solid tumours. Taiho Oncology’s pipeline products includes anti metabolic agents and selectively targeted agents. The company’s LONSURF is an anti-cancer drug for the treatment of metastatic colorectal cancer. Taiho Oncology is headquartered in Princeton, New Jersey, the US.

For a complete picture of TAS-0612’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.